Remove Clinical Development Remove Clinical Research Remove Pharmaceuticals
article thumbnail

Harnessing AI and Real-World Data: The Future of Clinical Development

PPD

The pharmaceutical industry is currently experiencing a significant transformation. The convergence of real-world data (RWD), technology and artificial intelligence (AI) is playing a vital role in accelerating drug development. Ready to learn more about convergence of real-world data and technology for clinical trials?

52
article thumbnail

Looking for Opportunities to Accelerate Clinical Research in Rare Diseases

LifeSciVC

It’s important to recognize that for many large pharmaceutical and biotechnology companies, compounds that have the potential to treat a rare disease of significant unmet need might become lower strategic priority than those that have mass market potential.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FSP Engagements Continue to Gain Popularity, Drive Success

PPD

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

article thumbnail

Reimagining CRO Partnerships: The Emerging Preference for Midsize Organizations

Conversations in Drug Development Trends

As the clinical research landscape continually evolves, the choice of a Contract Research Organization (CRO) partner can significantly impact the success of drug development programs. Discover how Worldwide is positioned to meet your needs with agility, expertise, and a truly personalized approach.

article thumbnail

The Power of Personalization Amid the Changing CRO Landscape

Conversations in Drug Development Trends

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture.

article thumbnail

Bayer extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease

The Pharma Data

The new FIND-CKD study extends our clinical research for finerenone to a non-diabetic population where the unmet need is high for brand spanking new treatments to delay disease progression.”.

article thumbnail

2024 predictions: Experts comment on AI, ML and automation

Drug Discovery World

In 2024, we can expect another wave of innovative new drugs to be developed using the technology, given that the AI-fuelled small molecule discovery pipeline is growing by almost 40% annually.” Fiona Maini, Senior Director Global Compliance and Strategy at Medidata “AI is dominating conversations across the drug discovery process.